Last reviewed · How we verify
optimized MMC
At a glance
| Generic name | optimized MMC |
|---|---|
| Also known as | optimized mitomycin-C |
| Sponsor | Turku University Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) (PHASE3)
- The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (PHASE3)
- A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- optimized MMC CI brief — competitive landscape report
- optimized MMC updates RSS · CI watch RSS
- Turku University Hospital portfolio CI